Biologics Contract Development Market, By Service Type, By Biologics Type, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.

The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) offer services ranging from early-stage research, process development, and clinical trials, to large-scale manufacturing. These partnerships help biopharma companies reduce costs, improve efficiency, and access specialized expertise. As the demand for biologics grows, driven by advancements in personalized medicine and rare diseases, the biologics contract development market continues to expand, with companies focusing on regulatory compliance, innovation, and cost-effective solutions.

Biologics Contract Development Market- Market Dynamics

Rising demand for personalized medicine driving biologics contract development growth.

The rising demand for personalized medicine is a significant driver for the biologics contract development market. Personalized medicine tailors' treatments to individual genetic profiles, improving efficacy and reducing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is projected to reach $3.5 trillion by 2025.

As biological therapies are central to personalized medicine, the need for specialized contract development services grows. The increasing prevalence of genetic disorders and cancer further fuels demand for biologics, with the NIH estimating that about 1 in 10 people globally are living with a rare disease, many requiring biological treatments. These factors have pushed biopharma companies to partner with contract development organizations to access the necessary expertise and scale production efficiently.

Biologics Contract Development Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.94% over the forecast period (2025-2032)

Based on Service Type segmentation, Contract Manufacturing was predicted to show maximum market share in the year 2024

Based on Biologics Type segmentation, Monoclonal Antibodies were the leading Biologics Type in 2024

Based on region, North America was the leading revenue generator in 2024

Biologics Contract Development Market- Segmentation Analysis:

The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.

The market is divided into three categories based on Service Type: Contract Research, Contract Manufacturing, and Contract Testing. The most dominant segment in the biologics contract development market is Contract Manufacturing. This segment has seen substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment needed to produce biologics efficiently while maintaining regulatory compliance. As biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and time-to-market. The need for scalable manufacturing solutions, particularly with the rise of personalized medicine and biological therapies for complex diseases, has solidified the importance of this segment.

The market is divided into four categories based on Biologics Type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. The most dominant segment in the biologics contract development market is Monoclonal Antibodies. This segment leads due to the growing demand for monoclonal antibodies (mAbs) in the treatment of various conditions, including cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. With advancements in biotechnology, many new mAbs have been developed, contributing to their widespread use in personalized medicine. As a result, contract development organizations (CDOs) are increasingly focused on providing services for the development and manufacturing of mAbs, making this segment the most prominent in the biologics contract development market.

Biologics Contract Development Market- Geographical Insights

North America holds a significant share of the biologics contract development market, driven by the robust healthcare infrastructure, strong research capabilities, and the high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. North America is home to several leading biopharma companies, academic institutions, and contract development organizations, making it a key hub for biologics development. The U.S. has a high incidence of chronic diseases, including cancer and autoimmune disorders, which further accelerates the demand for biologic treatments. Additionally, the region's healthcare policies support innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing manufacturing and development services to specialized CDOs also adds to the market's growth. With advancements in genomics and biotechnology, North America is positioned to continue leading in biologics development and contract services.

The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The U.S. Food and Drug Administration (FDA) provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The country has a high prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which propels the demand for biological treatments. Furthermore, the U.S. is a global leader in biotechnology and pharmaceutical innovation, with significant investments in personalized medicine, gene therapies, and monoclonal antibodies. The increasing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) allows biopharma companies to reduce costs and focus on innovation. Moreover, the U.S. government's support for research funding and regulatory incentives further strengthens the market landscape. With a growing emphasis on precision medicine, the biologics contract development market in the U.S. is expected to continue its strong growth trajectory.

Biologics Contract Development Market- Competitive Landscape:

The competitive landscape of the biologics contract development market is marked by the presence of several key players focusing on advanced technologies, regulatory compliance, and cost-effective solutions. Companies like Lonza Group, WuXi AppTec, and Samsung Biologics lead the market with their extensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. Lonza Group, for example, offers state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and regulatory adherence. These companies maintain strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in the biologic development space. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to fuel their competitive advantage.

Recent Developments:

In February 2023, Lonza expanded its footprint in the U.S. with the establishment of a new laboratory focused on developing drugs in the early stages of clinical trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Lonza Group
WuXi AppTec
Samsung Biologics
Catalent
Boehringer Ingelheim
AbbVie
Fujifilm Diosynth Biotechnologies
CordenPharma
Samsung Biologics
Patheon (Thermo Fisher Scientific)
Merck KGaA
KBI Biopharma
Recipharm
Minaris Regenerative Medicine
Syngene International
Rentschler Biopharma
Almac Group
Emergent BioSolutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032

Contract Research
Contract Manufacturing
Contract Testing

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032

Monoclonal Antibodies
Vaccines
Gene Therapies
Recombinant Proteins

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Pharmaceutical Companies
Biotechnology Companies
Academic & Research Institutions

GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4643

1. Biologics Contract Development Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Biologics Contract Development Market Snippet by Service Type
- 2.1.2. Biologics Contract Development Market Snippet by Biologics Type
- 2.1.3. Biologics Contract Development Market Snippet by End-User
- 2.1.4. Biologics Contract Development Market Snippet by Country
- 2.1.5. Biologics Contract Development Market Snippet by Region
2.2. Competitive Insights

3. Biologics Contract Development Key Market Trends

3.1. Biologics Contract Development Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Biologics Contract Development Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Biologics Contract Development Market Opportunities
3.4. Biologics Contract Development Market Future Trends

4. Biologics Contract Development Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Biologics Contract Development Market Landscape

6.1. Biologics Contract Development Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Biologics Contract Development Market - By Service Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
- 7.1.2. Contract Research
- 7.1.3. Contract Manufacturing
- 7.1.4. Contract Testing

Biologics Contract Development Market - By Biologics Type

7.2. Overview
- 7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
- 7.2.2. Monoclonal Antibodies
- 7.2.3. Vaccines
- 7.2.4. Gene Therapies
- 7.2.5. Recombinant Proteins

8. Biologics Contract Development Market - By End-User

8.1. Overview
- 8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
- 8.1.2. Pharmaceutical Companies
- 8.1.3. Biotechnology Companies
- 8.1.4. Academic & Research Institutions

9. Biologics Contract Development Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Biologics Contract Development Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
- 9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.2.7. The U.S.
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.2.8. Canada
  - 9.2.8.1. Overview
  - 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Biologics Contract Development Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
- 9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.7. Germany
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.8. UK
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.9. France
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.10. Italy
  - 9.3.10.1. Overview
  - 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.11. Spain
  - 9.3.11.1. Overview
  - 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.12. The Netherlands
  - 9.3.12.1. Overview
  - 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.13. Sweden
  - 9.3.13.1. Overview
  - 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.14. Russia
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.15. Poland
  - 9.3.15.1. Overview
  - 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.3.16. Rest of Europe
  - 9.3.16.1. Overview
  - 9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
- 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
- 9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.7. China
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.8. India
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.9. Japan
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.10. South Korea
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.11. Australia
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.12. Indonesia
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.13. Thailand
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.14. Philippines
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.4.15. Rest of APAC
  - 9.4.15.1. Overview
  - 9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
- 9.5.1. Overview
- 9.5.2. Biologics Contract Development Key Manufacturers in Latin America
- 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
- 9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.5.7. Brazil
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.5.8. Mexico
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.5.9. Argentina
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.5.10. Colombia
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.5.11. Rest of LATAM
  - 9.5.11.1. Overview
  - 9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
- 9.6.1. Overview
- 9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
- 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
- 9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
- 9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.7. Saudi Arabia
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.8. UAE
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.9. Israel
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.10. Turkey
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.11. Algeria
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.12. Egypt
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
- 9.6.13. Rest of MEA
  - 9.6.13.1. Overview
  - 9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
  - 9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
  - 9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Biologics Contract Development Industry

10.1. Competitive Dashboard
- 10.1.1. Competitive Benchmarking
- 10.1.2. Competitive Positioning
10.2. Company Profiles
- 10.2.1. Lonza Group
- 10.2.2. WuXi AppTec
- 10.2.3. Samsung Biologics
- 10.2.4. Catalent
- 10.2.5. Boehringer Ingelheim
- 10.2.6. AbbVie
- 10.2.7. Fujifilm Diosynth Biotechnologies
- 10.2.8. CordenPharma
- 10.2.9. Samsung Biologics
- 10.2.10. Patheon (Thermo Fisher Scientific)
- 10.2.11. Merck KGaA
- 10.2.12. KBI Biopharma
- 10.2.13. Recipharm
- 10.2.14. Minaris Regenerative Medicine
- 10.2.15. Syngene International
- 10.2.16. Rentschler Biopharma
- 10.2.17. Almac Group
- 10.2.18. Emergent BioSolutions

11. 360 Degree AnalystView

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us